Development
Predictive Oncology Inc.
POAI
$0.9386
-$0.0114-1.20%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.81M | 1.55M | 1.43M | 1.51M | 1.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.81M | 1.55M | 1.43M | 1.51M | 1.62M |
| Cost of Revenue | 540.20K | 541.50K | 515.80K | 505.10K | 487.90K |
| Gross Profit | 1.27M | 1.01M | 915.00K | 1.00M | 1.13M |
| SG&A Expenses | 16.11M | 16.83M | 16.23M | 16.27M | 16.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.65M | 17.37M | 16.75M | 16.77M | 16.87M |
| Operating Income | -14.84M | -15.82M | -15.32M | -15.27M | -15.26M |
| Income Before Tax | -18.42M | -19.32M | -25.79M | -25.74M | -26.24M |
| Income Tax Expenses | -- | -- | -- | -- | -661.70K |
| Earnings from Continuing Operations | -18.42 | -19.32 | -25.79 | -25.74 | -25.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.42M | -19.32M | -25.79M | -25.74M | -25.58M |
| EBIT | -14.84M | -15.82M | -15.32M | -15.27M | -15.26M |
| EBITDA | -13.93M | -14.74M | -14.09M | -13.95M | -13.90M |
| EPS Basic | -4.64 | -4.89 | -6.80 | -6.97 | -7.32 |
| Normalized Basic EPS | -2.32 | -2.47 | -2.43 | -2.54 | -2.65 |
| EPS Diluted | -4.64 | -4.89 | -6.81 | -6.97 | -7.38 |
| Normalized Diluted EPS | -2.32 | -2.47 | -2.43 | -2.54 | -2.65 |
| Average Basic Shares Outstanding | 15.93M | 15.82M | 15.41M | 14.74M | 14.08M |
| Average Diluted Shares Outstanding | 15.93M | 15.82M | 15.41M | 14.74M | 14.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |